Business Wire

GelSight Unveils Sleek Next Generation Mobile 3D Measurement Device to Expand into New Industries

Share

GelSight, a pioneer in tactile imaging and sensing technology, today introduced the latest version of its GelSight Mobile™ probe, the Series 2. This new generation of GelSight’s mobile device offers a sleek form-factor that is one-third lighter and less than half the volume of its predecessor, allowing it to scan surfaces in tighter spaces, while maintaining accuracy, speed, and field of view.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005405/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GelSight Mobile™ Series 2 offers industry-leading, tactile measurement capabilities in a more compact, ergonomic package. (Photo: Business Wire)

GelSight’s technology enables digital tactile sensing with the sensitivity and resolution of human touch. Data captured by GelSight’s elastomeric tactile sensing platform leverages proprietary software and algorithms to provide detailed, accurate surface characterization that can generate significant gains in productivity both on the production floor and in the field while also reducing the costs associated with manual or tool-based visual inspection. The handheld GelSight Mobile device can be deployed on production and assembly lines to enable rapid and well documented quality assurance decisions. Dimensions of scratches, dents, hits, gaps, offset, hole diameter, and fastener flushness can be measured in high-resolution, on any surface, in seconds.

The Series 2 head size has been minimized, so it can be utilized across a wider variety of applications. This is especially critical in the automotive and aerospace industries where it can provide rapid, repeatable, non-destructive testing for manufacturing and maintenance, repair, and overhaul (MRO) of engines, fuselages, and other critical components.

The Series 2 product addresses needs in new market verticals and creates new use cases as customers experience its game-changing performance first-hand. After bringing on new CEO, Youssef Benmokhtar, in June 2021, GelSight has set its sights on industries that can benefit from fast, accurate, micron-level measurements on a wide variety of surfaces, such as the additive manufacturing and energy sectors. The company will also continue to grow its core business in automotive, aerospace, and forensics.

“We took the accuracy, speed and mobility that our customers loved about the first-generation handheld device, and incorporated that into a smaller, more user-friendly form-factor that can deliver payback value in a matter of weeks in terms of saved production time, labor costs, and scrap,” said Youssef Benmokhtar, CEO, GelSight. “The introduction of Series 2 is ushering GelSight into a new era. We are digitizing tactile sensing to unlock new opportunities for in-line and off-line quality control innovation, across industries.”

“We use the GelSight Mobile for our MRO operations, and we are delighted to now incorporate the Mobile Series 2,” said Yann Siehen of Safran Helicopter Engines. “We had the opportunity to evaluate Series 2 and have been impressed by its performance. Its compact and lightweight design will definitely increase the number of use cases and will accelerate our return on investment.”

GelSight will be demoing the new device at the 2021 NBAA Business Aviation Convention & Exhibition (NBAA-BACE) October 12-14, 2021, in Las Vegas, NV at Booth #1224 – West Hall. To schedule a meeting and demo, please reach out to sales@gelsight.com.

The GelSight Mobile Series 2 is shipping now. To learn more about demo evaluations or purchasing, please email info@gelsight.com.

To learn more about GelSight, please visit https://gelsight.com/.

About GelSight

GelSight develops portable, non-destructive elastomeric 3D imaging systems used to improve quality control processes in aerospace, automotive and other high-value industries. The proprietary technology that was invented at the Massachusetts Institute of Technology provides extremely detailed and rapid surface measurements and robotic sensing capabilities. For more information, please visit https://gelsight.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Kalyn Schieffer for GelSight
kos@anzupartners.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye